1. Barker, P. E., Watson, M. S., Ticehurst, J. R., Colbert, J. C., and O'Connell, C. D. NIST physical standards for DNA-based medical testing. J. Clin. Lab. Anal. 16:5-10, 2002.

2. American College of Medical Genetics. Standards and Guidelines for Clinical Genetics Laboratories, 2nd ed., American College of Medical Genetics, Bethesda, MD.

3. Schooley, J. F. Responding to National Needs: The National Bureau of Standards Becomes the National Institute of Standards and Technology. 1969-1993.: US Government Printing Office Washington, DC, 2000.

4. Wells, R. D. and Warren, S. T. (eds.). Genetic Instabilities and Hereditary Neurological Disease. Academic, San Diego, CA, 1998.

5. Jakupciak, J. P. and Wells, R. D. Genetic instabilities of triplet repeat sequences by recombination. Life 50:355-359, 2000.

6. Evers-Kiebooms, G., Harper, P., Zoeteweij, M., et al. Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study. Eur. J. Hum. Genet. 10: 167-176, 2002.

7. O'Connell, C. D., Richie, K. L., Jakupciak, J. P., Amos, J., and Atha, D.H. Standardization of PCR amplification for fragile X trinucleotide repeat measurements. Clin. Genet. 61:13-20, 2002.

8. O'Connell, C. D. Standards for Nucleic Acid Diagnostic Applications, NIST, Gaithersburg, MD, 1998.

9. Emery, A. E. (ed.) Principles and Practice of Medical Genetics. Churchill Livingstone, Edinburgh, UK, 1997.

10. Chastain, P. D., Eichler, E. E., Kang, S., Nelson, D. L., Levene, S. D., and Sinden, R. R. Anomalous rapid electrophoretic mobility of DNA containing triplet repeats associated with human disease genes. Biochemistry. 34:16,125-16,131, 1995.

11. Eng, C., Brody, L. C., Wagner, T. M. U., et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J. Med. Genet. 38:824-833, 2001.

12. Kristensen, V. N., Kelefiotis, D., Kristensen, T., and Borresen-Dale, A-L. High-throughput methods for detection of genetic variation. Biotechniques 30:318-332, 2001.

13. Ellis, L. A., Taylor, C. F., and Taylor, G. R. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum. Mutat. 15:556-564, 2000.

14. Cotton, R. G. H. Mutation detection 2001: novel technologies, developments and applications for analysis of the human genome. Hum. Mutat. 19:313-314, 2002.

15. Cotton R. G. H. Slowly but surely towards better scanning for mutations. Trends Genet. 13:43-45, 1997.

16. O'Connell, C. D., Tully, L., Devaney, J. M., Marino, M., Jakupciak, J. P., and Atha, D. H. Renewable standard reference material for the detection of TP53 mutations. Mol. Diagn. 7:85-97, 2003.

17. O'Connell, C. D., Barker, P. E., Marino, M., et al. Molecular bio-markers used to detect cellular/genetic damage in tissue engineered skin, Schuttle, E. and Picciolo, G. L., eds., Tissue Engineered Medical Products. ASTM, West Conshohocken, PA, 2003.

18. Sunar-Reeder, B., Aydemir, S., Khan, A. R., et al. Use of TP53 reference materials to validate mutations in clinical tissue specimens by single-strand conformational polymorphism analysis. Mol. Diagn. 8:123-130,2004.

19. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. P53 mutations in human cancer. Science 253:49-53, 1991.

20. Vogelstein, B. and Kinzer, K. p53 function and dysfunction. Cell 70:523-526, 1992.

21. Somlo, G., Simpson, J. F., Frankel, P., et al. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br. J. Cancer 87:281-288, 2002.

22. Liu, M. C. and Gelmann, E. P. p53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 29:246-257, 2002.

23. Geisler, S., Lonning P. E., Aas, T.,et al. Influence of TP53 gene alterations and c-erb B-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505-2512, 2001.

24. Atha, D. H, Wenz, H-M., Morehead, H., Tian, J., and O'Connell, C. D. Detection of p53 point mutations by single strand conformation polymorphism: analysis by capillary electrophoresis. Electrophoresis 19:172-179, 1998.

25. Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA 86:2766-2770, 1989.

26. Eng, C., Brody L. C., Wagner, T. M. U., et al. Interpreting epidemi-ological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J. Med. Genet. 38:824-833, 2001.

27. Anderson, T. I. and Borresen, D. A.-L. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn. Mol. Pathol. 4:203-211, 1995.

28. Keller, G., Hartmann, A., Mueller, J., and Hofler, H. Denaturing high pressure chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab. Invest. 81:1735-1737, 2001.

29. Ahrendt, S. A., Halachmi, S, Chow, J. T, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. USA 96:7382-7387, 1999.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment